louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06826690: Comparative Factorial Study Design of Ultrasound Guided Wrist Block for Hand Surgery Comparing Effect of Bupivacane Alone and Bupivacane with Dexamethasone and Bupivacane with Dexametmiodine and Bupivacane with Dexamethasone and Dexametmiodine
Official title: A Comparative Factorial Study Design of Adjuvant Enhanced Ultrasound-Guided Wrist Block Anaesthesia for Hand Surgery : Bupivacane, Dexamethasone, Dexametmiodine
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Hand Surgeries
Lead sponsor: Aswan University
Sponsor class: OTHER
First posted: 2025-02-14
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: Ultrasound guided wrist block comparing effect of bupivacane alone and bupivacane with dexamethasone and bupivacane with dexametmiodine and bupivacane with dexamethasone and dexametmiodine

Detailed description: Ultrasound guided wrist block comparing effect of bupivacane alone and bupivacane with dexamethasone and bupivacane with dexametmiodine and bupivacane with dexametmiodine and dexamethasone.

Taking medical and surgical history from patients. Taking base line data as heart rate and blood pressure and spo2. Measure duration of analgesia for post operative pain using NRS for 24 hours abd recording NRS at time interval of 2 , 4,6,12,24 hours post operative.

Any patient the NRS above 4 will receive 5 mg nalbufin . Recording patients satisfaction by a survey .

Eligibility criteria: Inclusion Criteria:

- Patients more than or equal 18 years old and are ASA 1-3

Exclusion Criteria:

* allergy to used medication
* pre exist neuropathy
* coagulapthy
* cognitive impairment
* refusal to participate
* Failed block and requiring general anesthesia

Primary outcomes:
measure: Comparing the effectiveness of bupivacane alone and bupivacane with dexamethasone and bupivacane with dexametmiodine and bupivacane with dexamethasone and dexametmiodine
timeFrame: 24 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan university hospital
Study officials:
name: Zaher Zaki Zaher, Specialist
role: STUDY_DIRECTOR
References:
Clinical trial NCT03288090: Evaluate the Frequency of Fatigue After Cerebral Infarction
Official title: Fatigue After Stroke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Symptomatic Cerebral Infarction
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2017-09-19
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with cerebral infarction dating back one week at most

Brief summary: Cerebral infarction is a type of stroke that can lead to sometimes disabling sequelae. Among these sequelae, fatigue is frequently reported by patients. It is therefore important for doctors to understand why patients suffer from fatigue after cerebral infarction and to determine whether treatments given for the cerebral infarction may have an impact on this fatigue.

The aim of this research was to study the frequency of fatigue after cerebral infarction, the associated factors, in particular the impact of treatments administered in the acute phase.


Eligibility criteria: Inclusion Criteria:

* Patients presenting recent symptomatic cerebral infarction (\< 1 week) defined according to World Health Organization (WHO) criteria and hospitalised at the Stroke Unit in Dijon University.
* Patients aged 18 years or older.
* Patients who have been informed about the study, or their person of trust for patients unable to express their consent.

Exclusion Criteria:

* Patients (or their person of trust) who refuse to participate in the study.
* Subjects in custody.
* Patients presenting prior co-morbidity as a cause of significant fatigue in the opinion of the investigator
* Patients with dementia or aphasia before the stroke
* Patients (or their person of trust) who may be difficult to contact by telephone during the follow-up.

Primary outcomes:
measure: Fatigue evaluated using the Fatigue Severity Scale (FSS)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU Dijon Bourgogne
Study officials:
References:
Clinical trial NCT07019090: Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Official title: An Open-label Extension Trial of the Long-term Safety and Efficacy of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor: Haisco Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-06-13
Enrollment: 120
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459.

The primary object of this study is to find out how well people with idiopathic pulmonary fibrosis (IPF) tolerate long- term treatment with HSK44459.


Eligibility criteria: Inclusion Criteria:

1.IPF patients who completed the last dose treatment of HSK44459 in previous trials without prematurely discontinuing treatment permanently according to protocol , and have been evaluated by the researchers to have greater benefits than risks, and may benefit from continued treatment with HSK44459

Exclusion Criteria:

1. Patient will plan to undergo lung transplantation.
2. Patients with a Body Mass index (BMI) \<18.5 kg/m² that experienced an unexplained and clinically significant (\>10%) weight loss during the previous trials.
3. History of malignancy within 5 years prior to screening.
4. History of depression or anxiety disorder.

Primary outcomes:
measure: The incidence and severity of adverse events during the study period
timeFrame: Up to 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01023490: Vitamin D Treatment to Patients Suffering From Chronic Pain and Vitamin D Hypovitaminosis
Official title: A Randomised, Double-blind, Placebo-controlled Study to Check Whether Vitamin D Will Lead to a Decrease in Pain Intensity in Patients Suffering From Chronic Pain and Hypovitaminosis D
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Back Pain
Hypovitaminosis D
Keywords: back pain
hypovitaminosis D
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-12-02
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to check whether vitamin D will lead to a decrease in pain intensity compare to placebo, in patients suffering from chronic pain.

Detailed description: Vitamin D is a complex nutrient that functions as a hormone to benefit numerous body tissues.

Vitamin D is naturally produced by skin exposed to ultraviolet B. Despite the fact that Israel is a sunny country, a majority of all patients, and particularly those with pain, have inadequate intake of vitamin D.

Vitamin D therapy is easy for patients to self administer, well tolerated, and very economical.

In this study, we'll check whether vitamin D will lead to a decrease in pain intensity in patients suffering from chronic low back pain.

Eligibility criteria: Inclusion Criteria:

* men and women over 18, who suffer from chronic pain and hypovitaminosis D

Exclusion Criteria:

* patients that are treated with vitamin D

Primary outcomes:
measure: The objective of this study is to check whether vitamin D will lead to a decrease in pain intensity compare to placebo, in patients suffering from chronic pain.
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center, Pain Medicine Unit
Study officials:
References:
Clinical trial NCT01978990: Assessment of a Health Informatics System on Insulin-treated Diabetic Patients
Official title: Assessment of a Health Informatics System on Insulin-treated Diabetic Patients
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Type 1 or 2 Diabetics
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2013-11-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Type 1 or 2 diabetics diagnosed at least 12 months prior to study enrollment

Brief summary: Modern medicine provides many solutions that are intended to help control the patient's blood glucose level: insulin and other medications to lower it, glucose tablets or glucagone to raise it when it gets dangerously low, glucometers to quickly measure the blood glucose level, pumps and pens to inject insulin or other injectable medicine, etc.The objective of this trial is proving the concept and the feasibility of using a medical informatics system comprised of computer hardware, software and a smartphone application to achieve better outcomes.


Eligibility criteria: Inclusion Criteria:

1. Type 1 or 2 diabetics diagnosed at least 12 months prior to study enrollment.
2. Treated with insulin (basal only or basal + bolus) for at least 6 months prior to study enroment.
3. HbA1c lower than 12% With or without other anti-diabetic drugs.
4. 18-80 years of age.
5. Male or female.
6. Own an Android phone.
7. Able to handle mobile applications, technology-friendly
8. Able and willing to understand and comply with the study procedures.
9. Provide signed written and informed consent form prior to enrolment in the study.

Exclusion Criteria:

1. Using an insulin pump.
2. Pregnant or planning to be pregnant within the period of the study.
3. Active substance abuse.
4. Psychosis or schizophrenia under active care.
5. Uncorrected severe hearing or visual impairment.
6. Any other condition that is not acceptable to the investigator.

Primary outcomes:
measure: Recommendation accuracy
timeFrame: three months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00131690: Effect of Caffeine on Fetal Growth
Official title: The Importance of Caffeine in Fetal Growth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Birth Weight
Keywords: Caffeine
Coffee
Randomized
Birth weight
Lead sponsor: The Danish Epdiemiology Science Centre
Sponsor class: OTHER
First posted: 2005-08-19
Enrollment: 1200
Sex: FEMALE
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether caffeine has any effect on birth weight.


Eligibility criteria: Inclusion Criteria:

* Pregnant
* Consumption of at least 3 cups of coffee/day at recruitment

Exclusion Criteria:

* Gestational age more than 20 weeks at recruitment
* Chronic kidney disease
* Epilepsy
* Insulin dependent diabetes
* Metabolic disorder
* Previous low birth weight delivery
* Previous preterm delivery

Primary outcomes:
measure: birth weight
measure: gestational age
Secondary outcomes:
Other outcomes:
Locations:
city: Vennelyst Boulevard 6
country: Denmark
facility: Danish Epidemiology Science Centre
state: Aarhus
Study officials:
affiliation: Danish Epidemiology Science Centre
name: Jørn Olsen, Professor
role: STUDY_CHAIR
References:
citation: Bech BH, Obel C, Henriksen TB, Olsen J. Effect of reducing caffeine intake on birth weight and length of gestation: randomised controlled trial. BMJ. 2007 Feb 24;334(7590):409. doi: 10.1136/bmj.39062.520648.BE. Epub 2007 Jan 26.
Clinical trial NCT01995890: Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Official title: Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Intraocular Pressure
Keywords: nepafenac eye drops
intraocular pressure
Lead sponsor: Dr T V Patel Eye Institute
Sponsor class: OTHER
First posted: 2013-11-27
Enrollment: 327
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The Nevanac product information insert says that it can cause increase in eye pressure in 5-10% of patients. There is very little published literature on the effect of topical Nepafenac eye drops on eye pressure in normal people. The purpose of our study is to report this effect with a working hypothesis that there is no increase in eye pressure following use of Nepafenac eye drops.


Eligibility criteria: Inclusion Criteria:

* Best corrected visual acuity better than 20/80 in both eyes
* Intraocular pressure ≤21 mmHg in both eyes
* Open angles on 4 mirror gonioscopy without indentation
* Normal optic disc on stereoscopic examination and photographs

Exclusion Criteria:

* Change in the systemic medication profile during the course of the study
* Allergy to nepafenac molecule
* Corneal thinning/corneal infections
* Any intraocular surgery in past 3 months
* Pregnancy or those planning to conceive
* Breast feeding patients
* Unwillingness to participate in the trial
* Concomitant use of any other ocular drug (except artificial tears)

Primary outcomes:
measure: Intraocular pressure
timeFrame: 4 weeks
measure: Intraocular pressure
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Vadodara
country: India
facility: Dr TV Patel Eye Insititute
state: Gujarat
Study officials:
affiliation: TV Patel Eye Institute
name: Paaraj R Dave, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. doi: 10.1023/a:1007049015148.
citation: Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2006 Mar;90(3):314-7. doi: 10.1136/bjo.2005.080895.
citation: Warren KA, Fox JE. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina. 2008 Nov-Dec;28(10):1427-34. doi: 10.1097/IAE.0b013e31817e7ead.
Clinical trial NCT04382690: Behavioral Determinants That May Influence People's Hand-hygiene and Environment Disinfecting
Official title: Surveys of the Behavioral Determinants That May Influence People's Hand-hygiene and Environment Disinfecting in Different Countries
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hygiene
Lead sponsor: University of Warwick
Sponsor class: OTHER
First posted: 2020-05-11
Enrollment: 3975
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be residents of one of the following countries: Australia, China, India, Indonesia, Saudi Arabia, South Africa, and the United Kingdom.

Brief summary: An anonymous online survey will be conducted to measure the barriers and facilitators parents and teachers experience to positively influencing children's hand-hygiene. A sub-section of the survey will also examine the barriers and facilitators they experience to surface cleaning. The final survey will be conducted with participants from Australia, China, India, Indonesia, Saudi Arabia, South Africa, and the United Kingdom. The data collected will be completely anonymous and there are no sensitive questions. The primary and secondary analyses will focus on the hand-hygiene items to examine the survey's internal and external validity. The results will inform a future school-based intervention.


Eligibility criteria: Inclusion Criteria:

* be 18 years or older;
* identify as a female or male; and
* be either a teacher or parent of children between 5 and 10 years old.

Exclusion Criteria:

* be 17 years or younger;
* not identify as a female or male; and
* not be a teacher or parent of children between 5 and 10 years old.

Primary outcomes:
measure: Theoretical Domains Framework Barriers/Facilitators
timeFrame: Reported during the survey on Day 1
Secondary outcomes:
measure: Self-reported confience in positively influencing children's hygeine when they are watching
timeFrame: Reported during the survey on Day 1
measure: Self-reported confience in positively influencing children's hygeine when they are not watching
timeFrame: Reported during the survey on Day 1
measure: Self-reported hygiene
timeFrame: Reported during the survey on Day 1
Other outcomes:
measure: Country
timeFrame: Reported during the survey on Day 1
measure: Gender
timeFrame: Reported during the survey on Day 1
measure: Age
timeFrame: Reported during the survey on Day 1
measure: Parent or Teacher
timeFrame: Reported during the survey on Day 1
measure: Occupation
timeFrame: Reported during the survey on Day 1
Locations:
city: Coventry
country: United Kingdom
facility: University of Warwick
Study officials:
References:
Clinical trial NCT04278690: Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
Official title: A Randomized, Controlled Study of a Health Literacy-informed Technology-based Approach to Support Safe Medication Use by Parents After Discharge of Infants From the Neonatal Intensive Care Unit.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Medication Administered in Error
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2020-02-20
Enrollment: 425
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled study of parents of children to be discharged from the neonatal intensive care unit at Bellevue and Elmhurst hospitals. A total of 425 subjects will be recruited across two sites over preparatory phases and two primary study phases.

Detailed description: Our overarching goal is to promote safe medication use/adherence for high-risk infants, by leveraging health literacy approaches and mobile technology to reinforce provider counseling and support parent medication management after discharge from the NICU. We will adapt/integrate evidence-based strategies studied in less complex populations, for this vulnerable group. The HELPix (Health Education and Literacy for Parents) pictogram-based intervention, developed by our team, incorporates these strategies, with sizeable improvements found in medication knowledge, dosing errors, and adherence in outpatient general pediatric settings, but to date, HELPix has not been studied in NICU settings

Eligibility criteria: Inclusion Criteria:

1. English or Spanish-speaking
2. 18 years of age and older
3. Child discharged home with a Rx for \>1 daily liquid medication (other than multivitamin)
4. Primary person who will administers child's medications.
5. Willingness and ability to participate

Exclusion Criteria:

1. Does not have a working phone number
2. Does not have access to internet (via computer/smartphone)
3. Does not have a mobile phone that receives texts.
4. Not able to return to the hospital for their child's follow-up visit
5. Visual acuity worse than 20/50 according to the Rosenbaum Pocket Screener
6. Uncorrectable hearing impairment

Primary outcomes:
measure: Improvement in Dosing with HELPix+TECH and HELPix in comparison to usual care.
timeFrame: Visit 3 (Day 30)
measure: Improvement in medication adherence with HELPix+TECH and HELPix in comparison to usual care
timeFrame: Visit 3 (Day 30)
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone
name: Hsiang Sharon Yin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01757990: The Effect of Stevia Rebaudiana Extracts on Different Variables Related to Caries: an in Vitro and in Vivo Evaluation.
Official title: A Comparative Clinical Evaluation of the Effect of Stevia Rebaudiana Extracts and Sucrose on Dental Plaque pH (Stephan Curve Trend) Using a Microtouch Electrode in Healthy Volunteers. A Phase II Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dental Caries
Keywords: dental caries
Stevioside
Rebaudioside
plaque pH
Streptococcus mutans
Lead sponsor: Università degli Studi di Sassari
Sponsor class: OTHER
Collaborators: name: University of Milan
First posted: 2012-12-31
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The aim of the present investigation was to evaluate the effect of stevioside and rebaudioside on several variables related to caries development. Two approaches were performed: an in vitro evaluation of the growth of a culture of mutans streptococci and in vivo randomized study on the effect of a single rinse containing stevioside and rebaudioside on plaque-pH.


Eligibility criteria: Inclusion Criteria:

good general health, normal salivary secretion rate, normal buffer capacity

Exclusion Criteria:

systemic diseases, salivary secretion reduction, reduced buffer capacity

Primary outcomes:
measure: Plaque-pH modification
timeFrame: 5, 10, 15, 30, 45, 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: WHO Collaborating Centre for Community Dentistry and Oral Epidemiology University of Milan
name: Laura Strohmenger, MD
role: STUDY_CHAIR
References: